Search

everythinglearnresearchcommunity

for

Search:↓

The combination treatment showed a higher response rate but no significant survival benefits.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Topical dapsone gel reduced flare-ups in folliculitis decalvans without side effects.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

A new compound shows promise as a topical treatment for hair loss.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Dipotassium glycyrrhizinate helps wounds heal faster, especially in the early stages.

A new treatment for hair loss uses tiny lipid carriers to deliver a mix of minoxidil and latanoprost directly to hair follicles, promoting hair growth and being well tolerated by the skin.

Ritlecitinib works well and is safe for treating alopecia areata.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Topical Ruxolitinib may safely treat severe hair loss.

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Baricitinib successfully treated severe hair loss.

The combined treatment effectively managed severe skin issues in Olmsted syndrome.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.